UY36820A - Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por vrsh - Google Patents

Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por vrsh

Info

Publication number
UY36820A
UY36820A UY0001036820A UY36820A UY36820A UY 36820 A UY36820 A UY 36820A UY 0001036820 A UY0001036820 A UY 0001036820A UY 36820 A UY36820 A UY 36820A UY 36820 A UY36820 A UY 36820A
Authority
UY
Uruguay
Prior art keywords
monoclonal antibodies
human
synchriry
hybridides
vrsh
Prior art date
Application number
UY0001036820A
Other languages
English (en)
Inventor
Bueno Ramírez Susan Marcela
Kalergis Parra Alexis Mikes
Mora Alarcón Jorge Eugenio
Original Assignee
Pontificia Universidad Católica De Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pontificia Universidad Católica De Chile filed Critical Pontificia Universidad Católica De Chile
Publication of UY36820A publication Critical patent/UY36820A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

La presente invención se refiere a anticuerpos monoclonales o fragmentos del mismo que se unen a la proteína P del Virus Respiratorio Sincicial humano (VRSh) que comprenden una región variable de la cadena pesada que tiene una secuencia con al menos un 90%, 95% o 99% de identidad con la SEQ ID No:1 o SEQ ID 5 o una región variable de la cadena liviana que tiene una secuencia con al menos un 90%, 95% o 99% de identidad con la SEQ ID No:2 o SEQ ID No: 6.
UY0001036820A 2015-07-31 2016-07-27 Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por vrsh UY36820A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2015002152A CL2015002152A1 (es) 2015-07-31 2015-07-31 Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnostico de la infección causada por vrsh

Publications (1)

Publication Number Publication Date
UY36820A true UY36820A (es) 2017-01-31

Family

ID=56610056

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036820A UY36820A (es) 2015-07-31 2016-07-27 Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por vrsh

Country Status (17)

Country Link
US (2) US10858419B2 (es)
EP (2) EP3517546B1 (es)
KR (1) KR20180030919A (es)
CN (1) CN108474017B (es)
AR (1) AR105541A1 (es)
BR (1) BR112018002031A2 (es)
CA (1) CA2994219C (es)
CL (1) CL2015002152A1 (es)
CO (1) CO2018001010A2 (es)
ES (2) ES2786637T3 (es)
MX (2) MX2018001244A (es)
PE (2) PE20220004A1 (es)
PT (2) PT3328884T (es)
RU (1) RU2716990C2 (es)
UY (1) UY36820A (es)
WO (1) WO2017021815A2 (es)
ZA (1) ZA201800938B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017127857B4 (de) * 2017-11-24 2023-10-12 Lipozyt Marker UG (haftungsbeschränkt) Verwendung des ADIPOQ Genexpressionslevels zur Einordnung eines Probanden in Risikogruppen bei der Prognose oder Diagnose einer Diabetes mellitus Typ II Erkrankung
US20210347862A1 (en) * 2018-09-03 2021-11-11 Pontificia Universidad Catolica De Chile Specific monoclonal antibody against the n antigen of human respiratory syncytial virus (hrsv) useful for treating infection, detection thereof and diagnosis
CL2018003869A1 (es) * 2018-12-28 2021-01-15 Univ Pontificia Catolica Chile Anticuerpos monoclonales específicos para la proteína quimérica l del virus de la parainfluenza humana (piv), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por piv
EP3825591A1 (en) 2019-11-22 2021-05-26 Hamilton Sundstrand Corporation Hydraulic damping valve
CN113354734B (zh) * 2021-07-14 2021-12-14 北京祥瑞生物制品有限公司 一种快速检测病毒的试剂盒及其制备方法
CN115925909B (zh) * 2022-09-27 2023-07-21 深圳重链生物科技有限公司 抗呼吸道合胞病毒抗体及其相关应用
CN115838419B (zh) * 2022-09-27 2023-06-30 深圳重链生物科技有限公司 抗呼吸道合胞病毒抗体及其相关应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US7223410B1 (en) * 1994-08-05 2007-05-29 Sanofi Pasteur Limited Inactivated respiratory syncytial viral vaccines
US6258529B1 (en) * 1994-12-01 2001-07-10 Oravax, Inc. PCR amplification of rearranged genomic variable regions of immunoglobulin genes
US7527787B2 (en) * 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
MXPA04008088A (es) * 2002-02-21 2005-09-30 Medimmune Vaccines Inc Sistema de expresion del virus de parainfluenza recombinante y vacunas que comprenden antigenos heterologos derivados del metapneumovirus.
CA2494485A1 (en) * 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
EP1572108A4 (en) * 2002-09-27 2008-09-17 Medimmune Vaccines Inc FUNCTIONAL MUTATIONS OF RSV (RESPIRATORY SYNCYTIAL VIRUS)
EP1945669A4 (en) * 2005-08-15 2009-07-22 Arana Therapeutics Ltd CHIMERIC ANTIBODIES WITH NEUWELTPRIMATENREGIONEN
EP2363471B1 (en) * 2008-10-31 2016-10-12 Toray Industries, Inc. Immunoassay method for human cxcl1 protein
CL2011003002A1 (es) 2011-11-25 2012-05-25 Univ Pontificia Catolica Chile Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento.

Also Published As

Publication number Publication date
CA2994219A1 (en) 2017-02-09
BR112018002031A2 (pt) 2018-09-11
CN108474017A (zh) 2018-08-31
EP3517546B1 (en) 2020-02-26
US10858419B2 (en) 2020-12-08
KR20180030919A (ko) 2018-03-26
RU2018103933A (ru) 2019-08-28
PE20180576A1 (es) 2018-04-04
PT3517546T (pt) 2020-05-22
PT3328884T (pt) 2020-04-08
CL2015002152A1 (es) 2016-06-03
ZA201800938B (en) 2019-07-31
PE20220004A1 (es) 2022-01-05
CA2994219C (en) 2024-02-20
EP3517546A1 (en) 2019-07-31
RU2716990C2 (ru) 2020-03-17
CO2018001010A2 (es) 2018-04-30
WO2017021815A2 (en) 2017-02-09
EP3328884A4 (en) 2018-06-06
WO2017021815A3 (en) 2017-05-11
US11873331B2 (en) 2024-01-16
CN108474017B (zh) 2021-08-27
MX2018001244A (es) 2018-04-24
EP3328884A2 (en) 2018-06-06
RU2018103933A3 (es) 2019-08-28
US20210070844A1 (en) 2021-03-11
US20180327483A1 (en) 2018-11-15
ES2784888T3 (es) 2020-10-01
MX2022010471A (es) 2022-09-19
AR105541A1 (es) 2017-10-11
EP3328884B1 (en) 2020-01-01
ES2786637T3 (es) 2020-10-13

Similar Documents

Publication Publication Date Title
UY36820A (es) Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por vrsh
ES2543174T3 (es) Composición medicinal para el tratamiento y/o la prevención del cáncer
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
MX2022005253A (es) Anticuerpos neutralizantes de poliomavirus.
EA202092435A3 (ru) Моноклональные антитела против bcma
EA202091898A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
PE20150002A1 (es) Anticuerpos anti-fcrn
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
PE20190737A1 (es) Anticuerpos anti-cd27
CU24568B1 (es) Anticuerpo inhibidor de masp-3
PE20170665A1 (es) Anticuerpos anti-tau humanizados
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
BR112018010360A2 (pt) fragmentos fab de fator de complemento anti-c1q e utilizações dos mesmos
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
CO2020002060A2 (es) Anticuerpos multiespecíficos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
AR104250A1 (es) Anticuerpo anti-notch4 humano
CL2020002600A1 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
CO2017004753A2 (es) Anticuerpos que se unen a ccr6
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
BR112020015498A8 (pt) Anticorpos anti-pd-1
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
PE20141683A1 (es) Anticuerpos monoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs)
EA201890347A1 (ru) Антитела и исследования для обнаружения cd37
MX2021006865A (es) Anticuerpos anti-alfa-sinucleina y usos de estos.
BR112016015078A2 (pt) método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230807